Diabetes Care at Wake Forest Baptist Health
Diabetes mellitus is the pandemic of the new millennium. Wake Forest Baptist Health is committed to providing the best in clinical care and treatment for patients with diabetes. Research into the causes of diabetes is a major strength and area of emphasis at Wake Forest Baptist.
In early 2012, Wake Forest Baptist Health opened its Joslin Diabetes Center, one of 38 centers in the country. The Joslin Diabetes Center is an international leader in diabetes research, care and education and has been affiliated with Harvard Medical School since its founding in 1898.
Our goal is to help patients better manage diabetes (all types) and prevent the associated complications from the disease. Our multi-disciplinary team works to help patients get the care they need in one, easily accessible location.
And as an academic medical center, our patients get the benefit of research conducted here at Wake Forest Baptist Medical Center.
Ongoing diabetes research projects cover the spectrum – from focused laboratory studies aimed at understanding the molecular mechanisms that lead to diabetes – to population-based studies with the purpose of developing better methods for treatment and prevention of diabetes mellitus and the complications of diabetes.
Diabetes-related studies account for more than $38.2 million of research at the Medical Center.
The medical school has special strengths in several areas of diabetes research. Of note are studies of the genetic contributors to diabetes and diabetic complications, such as cardiovascular disease and nephropathy. Genetic research in minority populations is also a special area of emphasis.
In addition, WFBH is a major participant in NIH-sponsored clinical trials targeting diabetes prevention and prevention of cardiovascular disease and other complications in people with diabetes. There are numerous researchers investigating the influence of lipids, hormones, and blood pressure on the metabolic components of diabetes such as insulin resistance. In addition, we are a leader in stem cell research aimed at developing pancreatic ß-cells for the production of insulin.